This article has been updated from a previous version, which incorrectly identified the location of Atria's headquarters.
NEW YORK (GenomeWeb News) - Celera said today that it plans to acquire Atria Genetics in a $33 million cash deal that is expected to add transplant-related testing to the company’s molecular diagnostics portfolio.
Celera expects the acquisition to close during its second fiscal quarter, which ends Dec. 31. The company expects the deal to be accretive to earnings by the second half of its 2008 fiscal year, which ends June 30, 2008.
Atria, based in South San Francisco, Calif., makes a line of human leukocyte antigen testing products designed to identify potential donors for bone marrow transplantations, Celera said.
The companies have an existing relationship: In 2004, Abbott Molecular began distributing Atria’s HLA sequencing products through its alliance with Celera.
Celera said today that the HLA market is around $175 million, of which around $20 million comes from bone marrow transplantation and the bone marrow registry.
Celera’s president, Kathy Ordoñez, said the Atria acquisition “gives us direct access to this important niche market area of tissue typing in transplantation and the bone marrow registry markets.”
Celera said it will integrate Atria’s 13 employees into its ranks.